ReviewBlood cancer discovery2025
Minimal Residual Disease as an Early Endpoint for Accelerated Drug Approval in Myeloma: A Roadmap.
Review in Blood cancer discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Increasing Trends of Minimal Residual Disease Measurement in Trials Focusing on Multiple Myeloma Treatment: A Systematic Analysis of Clinical Research Design From 2014 to 2025.European journal of haematology · 2026Pooled it
- Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials.Journal of the National Cancer Institute · 2026Pooled it
- Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS.Blood advances · 2026Trial
- A framework to evaluate surrogate endpoints at the trial level: analysis in colorectal cancer.Journal of the National Cancer Institute · 2026Article
- Clinical implications of minimal residual disease monitoring in multiple myeloma.International journal of hematology · 2026Review
- The Evolving Role of Genomic Technologies in Multiple Myeloma: Implications for Diagnosis, Risk Stratification and Resistance.Molecular diagnosis & therapy · 2026Review
- Challenges and Potential Solutions to Advance Global Cancer Drug Development.Therapeutic innovation & regulatory science · 2026Review
- Review
- IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM.Blood advances · 2026Article
- Review
- Measurable residual disease testing in acute myeloid leukemia: current state, foundational models, and tools for future development.Cancer metastasis reviews · 2026Review
- Dynamic Targetable Extracellular Vesicle Surface Proteins Monitor Depth of Response to CAR T Therapy.Research square · 2026Article
- Identification of Extracellular Vesicle Signatures of Daratumumab Treated Multiple Myeloma.Journal of extracellular vesicles · 2026Article
- RNA-Based Therapeutic Strategies in Multiple Myeloma: From Molecular Targets to Delivery and Clinical Translation.International journal of molecular sciences · 2026Review
- Developing MRD as an early endpoint for accelerated approval in CLL.Seminars in hematology · 2025Review
- EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma.Nature reviews. Clinical oncology · 2025Review
- MRD in multiple myeloma: the clinical perspective.Frontiers in oncology · 2025Review
- Novelties on Multiple Myeloma from the Main 2024 Hematology Conferences.Mediterranean journal of hematology and infectious diseases · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
significanceThe acceptance of MRD-negative complete response as an endpoint that is reasonably likely to predict clinical benefit will allow for the design of streamlined clinical trials for accelerated approval, enabling significantly faster patient access to novel therapies. Cooperative efforts were required to obtain and analyze clinical trial data from multiple sponsors and to determine the best approach to analysis with a relatively limited number of available datasets. The process to evaluate MRD as an intermediate endpoint, undertaken jointly by myeloma researchers and industry, with feedback from the FDA, serves as a roadmap for other areas of oncology to develop intermediate endpoints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.